| Predicate |
Object |
| contentType |
Journal Article |
| endingPage |
6 |
| issn |
0890-9091 |
| issueIdentifier |
5 |
| pageRange |
425-6 |
| publicationName |
Oncology (Williston Park, N.Y.) |
| startingPage |
425 |
| bibliographicCitation |
Davidson NE. HER2-targeted therapies: how far we've come--and where we're headed. Oncology (Williston Park). 2011 Apr 30;25(5):425–6. PMID: 21710840. |
| creator |
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4b5ae5620267f178d26cf6aad7618dc8 |
| date |
2011-04-30^^<http://www.w3.org/2001/XMLSchema#date> |
| identifier |
https://pubmed.ncbi.nlm.nih.gov/21710840 |
| isPartOf |
https://portal.issn.org/resource/ISSN/0890-9091
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1783 |
| language |
English |
| source |
https://pubmed.ncbi.nlm.nih.gov/ |
| title |
HER2-targeted therapies: how far we've come--and where we're headed |
| discusses |
http://id.nlm.nih.gov/mesh/M0001483
http://id.nlm.nih.gov/mesh/M0556300
http://id.nlm.nih.gov/mesh/M0001357
http://id.nlm.nih.gov/mesh/M0473129
http://id.nlm.nih.gov/mesh/M0018336
http://id.nlm.nih.gov/mesh/M0291428 |
| hasPrimarySubjectTerm |
http://id.nlm.nih.gov/mesh/D000970Q000627
http://id.nlm.nih.gov/mesh/D000911Q000627
http://id.nlm.nih.gov/mesh/D001943Q000188
http://id.nlm.nih.gov/mesh/D011799Q000627
http://id.nlm.nih.gov/mesh/D018734 |
| hasSubjectTerm |
http://id.nlm.nih.gov/mesh/D016503
http://id.nlm.nih.gov/mesh/D061067
http://id.nlm.nih.gov/mesh/D005260
http://id.nlm.nih.gov/mesh/D000077341
http://id.nlm.nih.gov/mesh/D002986
http://id.nlm.nih.gov/mesh/D001943Q000235
http://id.nlm.nih.gov/mesh/D000068878
http://id.nlm.nih.gov/mesh/D006801 |
| discussesAsDerivedByTextMining |
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_43830973f74de180729ad1e755d592ad
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_e8ad08f759b2798c1b5dca78861cc6ce |